These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9865132)

  • 1. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
    Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
    Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor marker in ovarian cancer].
    Komai K; Nishida T
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
    Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
    Lukácskó I; Hernádi Z; Sápy T; Borsos A
    Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
    Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
    Karlan BY; McIntosh M
    J Clin Oncol; 2007 Apr; 25(11):1303-4. PubMed ID: 17416848
    [No Abstract]   [Full Text] [Related]  

  • 11. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J; Qian H; Tian Y
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
    Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
    García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
    Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report.
    Faggiano P; D'Aloia A; Bignotti T; Dei Cas L
    Ital Heart J; 2003 Jul; 4(7):497-9. PubMed ID: 14558304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.